Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
TL;DR
- Retatrutide, Eli Lilly's next-generation obesity drug, successfully completed its first late-stage trial for Type 2 diabetes patients.
- The drug lowered hemoglobin A1c levels by an average of 1.7% to 2% across different doses at 40 weeks.
- Patients on the highest dose lost an average of 16.8% of their body weight at 40 weeks.
- Retatrutide mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon.
- The drug's safety profile showed primarily gastrointestinal side effects, similar to other injectable diabetes and obesity drugs.
- Eli Lilly expects to report findings from seven additional phase three trials on retatrutide by the end of the year.